利福昔明在肝硬化相关并发症中的应用.

Patients with liver cirrhosis often die of complications, among which hepatic encephalopathy is the primary cause of death and upper gastrointestinal bleeding is the most common complication of liver cirrhosis. In recent years, with the continuous progress in the research on intestinal flora and inflammatory response in patients with liver cirrhosis, rifaximin, a selective oral antibacterial agent, has attracted more and more attention in China and foreign countries. This article analyzes the studies on rifaximin in the treatment of complications associated with liver cirrhosis, in order to provide reasonable suggestions for subsequent studies and clinical practice. [ABSTRACT FROM AUTHOR]